NewGenIvf Group Limited
NIVFHealthcareNASDAQMedical Care Facilities · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NewGenIvf Group Limited focuses on Medical Care Facilities services and products. NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and. At a $2.4M market cap, NewGenIvf Group Limited ranks as a micro-cap company within healthcare. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
Market Cap
$2.4M
Beta
-0.04
P/E (TTM)
0.00
P/E (Fwd)
0.01
EPS (TTM)
$328.32
EPS (Fwd)
$84.06
ROE
79.4%
ROA
-36.9%
Cash
$958,556
Total Debt
$4.9M
Free CF
-$10.5M
52W Change
-99.9%
Annual Financials
Cash vs Debt
Where NIVF stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, NIVF finished 70.51% below its 150-day moving average ($4.51) and 89.70% below its 200-day moving average ($12.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NIVF overbought or oversold?
At the September 2, 2026 close, NIVF's RSI(14) was 78.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, NIVF has $959K in cash with $4.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$10.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 79.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.9M (2022) to $4.7M (2025), a 20% decline worth watching.
NIVF's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NIVF.